Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07GAA
|
|||
| Former ID |
DIB004934
|
|||
| Drug Name |
Lonapegsomatropin
|
|||
| Synonyms |
ACP-001; TransCon-PEG Growth Hormone; TransCon-PEG-hGH; Growth hormone (TransCon, subcutaneous sustained-release), Ascendis Pharma
Click to Show/Hide
|
|||
| Indication | Growth failure [ICD-11: LD2F.1Y] | Approved | [1] | |
| Growth hormone deficiency [ICD-11: 5A61.3] | Phase 2 | [2] | ||
| Company |
Ascendis Pharma
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 761177. | |||
| REF 2 | ClinicalTrials.gov (NCT01947907) Safety, PK/PD and Efficacy of ACP-001 Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD). U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.